

## Cyltezo<sup>®</sup> (adalimumab-adbm) – Correction - high concentration formulation approved as biosimilar, not interchangeable

- On May 1, 2024, [Boehringer Ingelheim announced](#) the FDA approval of [Cyltezo \(adalimumab-adbm\)](#) citrate-free, high concentration (40 mg/0.4 mL) injection, biosimilar to AbbVie's [Humira<sup>®</sup> \(adalimumab\)](#).
  - Cyltezo was previously launched as biosimilar and *interchangeable* to Humira in the low concentration strengths (40 mg/0.8 mL, 20 mg/0.4 mL, and 10 mg/0.2 mL).
  - There are five other high concentration biosimilar formulations approved for Humira: [Amjevita<sup>™</sup> \(adalimumab-atto\)](#), [Hyrimoz<sup>®</sup> \(adalimumab-adaz\)](#), [Hadlima<sup>™</sup> \(adalimumab-bwwd\)](#), [Simlandi<sup>®</sup> \(adalimumab-ryyk\)](#), and [Yuflyma<sup>®</sup> \(adalimumab-aaty\)](#).
  - Hyrimoz (80 mg/0.8 mL, 20 mg/0.2 mL, 10 mg/0.1 mL) and Simlandi (40 mg/0.4 mL) have been granted [interchangeability](#).
- Cyltezo high-concentration formulation is priced at a 5% discount to Humira under the brand name Cyltezo and at an 81% discount to Humira as the unbranded product adalimumab-adbm.
- Cyltezo high concentration formulation is available as a 40 mg/0.4 mL single-dose pen and single-dose prefilled syringe.